Page 63 - Demo

www.psypharma.ru %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430 %u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430 %u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 %u2116 4/2024%u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d.63%u041d%u041e%u0412%u042b%u0415 %u041b%u0415%u041a%u0410%u0420%u0421%u0422%u0412%u0415%u041d%u041d%u042b%u0415 %u0421%u0420%u0415%u0414%u0421%u0422%u0412%u0410%u043b%u0438%u0442%u0435%u0440%u0430%u0442%u0443%u0440%u0430 References1. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe %u2014 a critical review and appraisal of 27 studies // Eur Neuropsychopharmacoi. %u2013 2005. %u2013 Vol. 15 (4). %u2013 Pp. 357%u2013376. %u2013 https://doi.org/10.1016/j.euroneuro.2005.04.0121. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe %u2014 a critical review and appraisal of 27 studies // Eur Neuropsychopharmacoi. %u2013 2005. %u2013 Vol. 15 (4). %u2013 Pp. 357%u2013376. %u2013 https://doi.org/10.1016/j.euroneuro.2005.04.0122. Kong W., Deng H., Wan J., Zhou Y., Zhou Y., Song B., Wang X. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: A systematic review and network meta-analysis of double-blind randomized controlled trials // Front Pharmacol. %u2013 2020. %u2013 Vol. 11. %u2013 Art. 580858. %u2013 https://doi.org/10.3389/fphar.2020.5808582. Kong W., Deng H., Wan J., Zhou Y., Zhou Y., Song B., Wang X. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: A systematic review and network meta-analysis of double-blind randomized controlled trials // Front Pharmacol. %u2013 2020. %u2013 Vol. 11. %u2013 Art. 580858. %u2013 https://doi.org/10.3389/fphar.2020.5808583. Yu W., Singh S.S., Calhoun S., Zhang H., Zhao X., Yang F. Generalized anxiety disorder in urban China: Prevalence, awareness, and disease burden // J Affect Disord. %u2013 2018. %u2013 Vol. 234. %u2013 Pp. 89%u201396. %u2013 https://doi.org/10.1016/j.jad.2018.02.0123. Yu W., Singh S.S., Calhoun S., Zhang H., Zhao X., Yang F. Generalized anxiety disorder in urban China: Prevalence, awareness, and disease burden // J Affect Disord. %u2013 2018. %u2013 Vol. 234. %u2013 Pp. 89%u201396. %u2013 https://doi.org/10.1016/j.jad.2018.02.0124. Etkin A., Prater K.E., Schatzberg A.F. et al Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder // Arch Gen Psychiatry. %u2013 2009. %u2013 Vol. 66 (12). %u2013 Pp. 1361%u20131372. 4. Etkin A., Prater K.E., Schatzberg A.F. et al Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder // Arch Gen Psychiatry. %u2013 2009. %u2013 Vol. 66 (12). %u2013 Pp. 1361%u20131372. 5. Nutt D., Argyropoulos S., Hood S., Potokar J. Generalized anxiety disorder: A comorbid disease // Eur Neuropsychopharmacoi. %u2013 2006. %u2013 Vol. 16, suppl. 2. %u2013 Pp. S109%u2013S118.5. Nutt D., Argyropoulos S., Hood S., Potokar J. Generalized anxiety disorder: A comorbid disease // Eur Neuropsychopharmacoi. %u2013 2006. %u2013 Vol. 16, suppl. 2. %u2013 Pp. S109%u2013S118.6. Roberge P., Normand-Lauziere F., Raymond I. et al. Generalized anxiety disorder in primary care: Mental health services use and treatment adequacy // BMC Earn Pract. %u2013 2015. %u2013 Vol. 16. %u2013 Art. 146. %u2013 https://doi.org/10.1186/s12875-015-0358-y6. Roberge P., Normand-Lauziere F., Raymond I. et al. Generalized anxiety disorder in primary care: Mental health services use and treatment adequacy // BMC Earn Pract. %u2013 2015. %u2013 Vol. 16. %u2013 Art. 146. %u2013 https://doi.org/10.1186/s12875-015-0358-y7. Mosolov S.N., Martynikhin I.A., Syunyakov T.S., Galankin T.L., Neznanov N.G. Incidence of the diagnosis of anxiety disorders in the Russian Federation: Results of a web-based survey of psychiatrists // Neurology and Therapy. %u2013 2021. %u2013 Pp. 1%u201314. %u2013https://doi.org/10.1007/s40120-021-00277-w7. Mosolov S.N., Martynikhin I.A., Syunyakov T.S., Galankin T.L., Neznanov N.G. Incidence of the diagnosis of anxiety disorders in the Russian Federation: Results of a web-based survey of psychiatrists // Neurology and Therapy. %u2013 2021. %u2013 Pp. 1%u201314. %u2013https://doi.org/10.1007/s40120-021-00277-w8. Stein D.J., Ahokas A., M%u0430%ue088rquez M.S., H%u00f6schl C., Oh S., Jarema M., Avedisova A.S., Albarran Cr., Olivier V. Agomelatine in generalized anxiety disorder: An active comparator and placebo- controlled study // J Clin Psychiatry. %u2013 2014. %u2013 Vol. 75 (4). %u2013 Pp. 362%u2013368. %u2013 https://doi.org/10.4088/JCP.13m084338. Stein D.J., Ahokas A., M%u0430%ue088rquez M.S., H%u00f6schl C., Oh S., Jarema M., Avedisova A.S., Albarran Cr., Olivier V. Agomelatine in generalized anxiety disorder: An active comparator and placebo- controlled study // J Clin Psychiatry. %u2013 2014. %u2013 Vol. 75 (4). %u2013 Pp. 362%u2013368. %u2013 https://doi.org/10.4088/JCP.13m084339. Jackson J.L., Houston J.S., Hanling S.R. et al. Clinical predictors of mental disorders among medical outpatients // Arch Intern Med. %u2013 2001. %u2013 Vol. 161 (6). %u2013 Pp. 875%u2013879. %u2013https://doi.org/10.1001/achirt.1n6e1.6.875PMdbeu9. Jackson J.L., Houston J.S., Hanling S.R. et al. Clinical predictors of mental disorders among medical outpatients // Arch Intern Med. %u2013 2001. %u2013 Vol. 161 (6). %u2013 Pp. 875%u2013879. %u2013https://doi.org/10.1001/achirt.1n6e1.6.875PMdbeu10. Andrews G., Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis // Psychopathology. %u2013 2002. %u2013 Vol. 35 (2-3). %u2013 Pp. 100%u2013106. %u2013https://doi.org/101.159/000065127PubMed10. Andrews G., Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis // Psychopathology. %u2013 2002. %u2013 Vol. 35 (2-3). %u2013 Pp. 100%u2013106. %u2013https://doi.org/101.159/000065127PubMed11. Papadimitriou G.N., Linkowski P. Sleep disturbance in anxiety disorders // Int Rev Psychiatry. %u2013 2005. %u2013 Vol. 17 (4). %u2013 Pp. 229%u2013236. %u2013https://doi.org/10d.o1080/095402605001045Pu2b4dMe11. Papadimitriou G.N., Linkowski P. Sleep disturbance in anxiety disorders // Int Rev Psychiatry. %u2013 2005. %u2013 Vol. 17 (4). %u2013 Pp. 229%u2013236. %u2013https://doi.org/10d.o1080/095402605001045Pu2b4dMe12. Rickels K., Schweizer E. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment // Br J Psychiatry. %u2013 1998. %u2013 Vol. 34. %u2013 Pp. 49%u201354.12. Rickels K., Schweizer E. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment // Br J Psychiatry. %u2013 1998. %u2013 Vol. 34. %u2013 Pp. 49%u201354.13. Stein D.J., Ahokas A., Jarema M., Avedisova A.S., Vavrusova L., Chaban O., Gruget C., Olivier V., Picarel-Blanchot F., de Bodinat C. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study // Eur Neuropsychopharmacol. %u2013 2017. %u2013 Vol. 27 (5). %u2013 Pp. 526%u2013537. %u2013 https://doi.org/10.1016/j.euroneuro.2017.02.00713. Stein D.J., Ahokas A., Jarema M., Avedisova A.S., Vavrusova L., Chaban O., Gruget C., Olivier V., Picarel-Blanchot F., de Bodinat C. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study // Eur Neuropsychopharmacol. %u2013 2017. %u2013 Vol. 27 (5). %u2013 Pp. 526%u2013537. %u2013 https://doi.org/10.1016/j.euroneuro.2017.02.00714. Stein D.J., Khoo J.P., Ahokas A., Jarema M., Van Ameringen M., Vavrusova L., H%u04e7 schl C., Bauer M., Bitter I., Mosolov S.N., Olivier V., Matharan S., Picarel-Blanchot F., de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25%u201350 mg/day) versus escitalopram (10%u201320 mg/day) in out-patients with severe generalized anxiety disorder // Eur Neuropsychopharmacol. %u2013 2018. %u2013 Vol. 28 (8). %u2013 Pp. 970%u2013979. %u2013 https://doi.org/10.1016/j.euroneuro.2018.05.00614. Stein D.J., Khoo J.P., Ahokas A., Jarema M., Van Ameringen M., Vavrusova L., H%u04e7 schl C., Bauer M., Bitter I., Mosolov S.N., Olivier V., Matharan S., Picarel-Blanchot F., de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25%u201350 mg/day) versus escitalopram (10%u201320 mg/day) in out-patients with severe generalized anxiety disorder // Eur Neuropsychopharmacol. %u2013 2018. %u2013 Vol. 28 (8). %u2013 Pp. 970%u2013979. %u2013 https://doi.org/10.1016/j.euroneuro.2018.05.00615. Norton P.J., Temple S.R., Pettit J.W. Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression? // J Behav Ther Exp Psychiatry. %u2013 2008. %u2013 Vol. 39 (4). %u2013 Pp. 515%u2013525. %u2013 https://doi.org/10.1016/j.jbtep.2007.10.01015. Norton P.J., Temple S.R., Pettit J.W. Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression? // J Behav Ther Exp Psychiatry. %u2013 2008. %u2013 Vol. 39 (4). %u2013 Pp. 515%u2013525. %u2013 https://doi.org/10.1016/j.jbtep.2007.10.01016. Haby M.M., Donnelly M., Corry J., Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: A meta-regression of factors that may predict outcome // Aust N.Z.J. Psychiatry. %u2013 2006. %u2013 Vol. 40. %u2013 Pp. 9%u201319.16. Haby M.M., Donnelly M., Corry J., Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: A meta-regression of factors that may predict outcome // Aust N.Z.J. Psychiatry. %u2013 2006. %u2013 Vol. 40. %u2013 Pp. 9%u201319.17. Kessler R.C., Brandenburg N., Lane M. et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication // Psychol Med. %u2013 2005. %u2013 Vol. 35 (7). %u2013 Pp. 1073%u20131082. %u2013https://doi.org/10d.1o017/S003329150045783PbudMe17. Kessler R.C., Brandenburg N., Lane M. et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication // Psychol Med. %u2013 2005. %u2013 Vol. 35 (7). %u2013 Pp. 1073%u20131082. %u2013https://doi.org/10d.1o017/S003329150045783PbudMe18. Wittchen H.U. Generalized anxiety disorder: Prevalence, burden, and cost to society // Depress Anxiety. %u2013 2002. %u2013 Vol. 16 (4). %u2013 Pp. 162%u2013171. %u2013https://doi.org/10.1002/da.10506PMuebd18. Wittchen H.U. Generalized anxiety disorder: Prevalence, burden, and cost to society // Depress Anxiety. %u2013 2002. %u2013 Vol. 16 (4). %u2013 Pp. 162%u2013171. %u2013https://doi.org/10.1002/da.10506PMuebd19. Doyle A.C., Pollack M.H. Establishment of remission criteria for anxiety disorders // J Clin Psychiatr. %u2013 2003. %u2013 Vol. 64, suppl. 15. %u2013 Pp. 40%u201345.19. Doyle A.C., Pollack M.H. Establishment of remission criteria for anxiety disorders // J Clin Psychiatr. %u2013 2003. %u2013 Vol. 64, suppl. 15. %u2013 Pp. 40%u201345.20. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder // Int J Neuropsychopharmacol. %u2013 2011. %u2013 Vol. 14. %u2013Pp. 697%u2013710. %u2013 https://doi.org/10.1017/s146114571000143420. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder // Int J Neuropsychopharmacol. %u2013 2011. %u2013 Vol. 14. %u2013Pp. 697%u2013710. %u2013 https://doi.org/10.1017/s146114571000143421. Tyrer P., Baldwin D. Generalised anxiety disorder // Lancet. %u2013 2006. %u2013 Vol. 368. %u2013Pp. 2156%u20132166. %u2013 https://doi.org/10.1016/s0140-6736(06)69865-621. Tyrer P., Baldwin D. Generalised anxiety disorder // Lancet. %u2013 2006. %u2013 Vol. 368. %u2013Pp. 2156%u20132166. %u2013 https://doi.org/10.1016/s0140-6736(06)69865-6